AU5866600A - The use of human fgh-8 polypeptides as neurotrophic agents - Google Patents

The use of human fgh-8 polypeptides as neurotrophic agents

Info

Publication number
AU5866600A
AU5866600A AU58666/00A AU5866600A AU5866600A AU 5866600 A AU5866600 A AU 5866600A AU 58666/00 A AU58666/00 A AU 58666/00A AU 5866600 A AU5866600 A AU 5866600A AU 5866600 A AU5866600 A AU 5866600A
Authority
AU
Australia
Prior art keywords
fgh
polypeptides
human
neurotrophic agents
neurotrophic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58666/00A
Inventor
Jai Pal Singh
Asavari Prasad Wagle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU5866600A publication Critical patent/AU5866600A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
AU58666/00A 1999-06-29 2000-06-21 The use of human fgh-8 polypeptides as neurotrophic agents Abandoned AU5866600A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14154999P 1999-06-29 1999-06-29
US60141549 1999-06-29
PCT/US2000/011885 WO2001000662A2 (en) 1999-06-29 2000-06-21 The use of human fgh-8 polypeptides as neurotrophic agents

Publications (1)

Publication Number Publication Date
AU5866600A true AU5866600A (en) 2001-01-31

Family

ID=22496178

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58666/00A Abandoned AU5866600A (en) 1999-06-29 2000-06-21 The use of human fgh-8 polypeptides as neurotrophic agents

Country Status (2)

Country Link
AU (1) AU5866600A (en)
WO (1) WO2001000662A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414019B2 (en) * 2002-10-04 2008-08-19 Auckland Uniservices Limited FGF-8 methods of use
US7935342B2 (en) 2006-02-02 2011-05-03 Rinat Neuroscience Corp. Methods for treating obesity by administering a trkB antagonist
WO2015121457A1 (en) 2014-02-13 2015-08-20 Westphal Sören Fgf-8 for use in treating diseases or disorders of energy homeostasis
KR102489706B1 (en) 2015-10-31 2023-01-17 아이오 테라퓨틱스, 인크. Treatment of nervous system disorders using combinations of rxr agonists and thyroid hormones

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4995193A (en) * 1992-08-04 1994-03-03 Regeneron Pharmaceuticals, Inc. Method of enhancing differentiation and survival of neuronal precursor cells
AU6284194A (en) * 1993-03-12 1994-09-26 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Treatment of motor neuron diseases with fibroblast growth factor-5 (fgf-5)

Also Published As

Publication number Publication date
WO2001000662A2 (en) 2001-01-04
WO2001000662A3 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
EP1212327B8 (en) Pyrazolopyrimidines as therapeutic agents
AU4431000A (en) Novel use
AU1438001A (en) 27 human secreted proteins
AU7882900A (en) Hydrotherapy bed
AU1448701A (en) 15 human secreted proteins
AU1334101A (en) 19 human secreted proteins
AU1608201A (en) Human zven proteins
AU4338100A (en) Secreted human proteins
AU2451500A (en) Therapeutic agents
AU1342501A (en) 32 human secreted proteins
AU1804801A (en) Neurotrophic bicyclic diamides
AU5866600A (en) The use of human fgh-8 polypeptides as neurotrophic agents
AU2271801A (en) Human slit polypeptide zslit3
AU5973600A (en) Therapeutic agents
AU2399601A (en) Novel tachykinin-like polypeptides and use thereof
AU1449001A (en) 28 human secreted proteins
AU3064800A (en) The therapeutic use of r-warfarin as anticoagulant
AU4456800A (en) Human hac3
AU7999300A (en) Novel human phosphodiesterase zcytor13
PL350963A1 (en) Use of arylalkanoylpyridazines
EP1194439A4 (en) Human eag2
AU1472801A (en) 24 human secreted proteins
AU1581301A (en) Human chemokine beta-13
AU2001285707A1 (en) Peptides of the alpha1-adrenergic receptor and their use for psoriasis
AU6150200A (en) Therapeutic agents

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase